Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan in Acute Respiratory Failure Due to COVID-19
NCT04510662Phase 2Completed
- Start
- Aug 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of telmisartan in coronavirus disease 2019 (COVID-19) and acute respiratory failure (ARF) (2 arms). Primary endpoints: Death at 30 days and Mechanical ventilation at 14 days. Started Aug 2020; status: completed.
02
Drugs
telmisartan
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory failure (ARF)
Beyond the preview
Go deeper on NCT04510662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510662.